64 completed. 64 Phase 3, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 64 | Completed 64 |
| Phase 2 | 8 | Completed 8 |
Follow Prostatic Hyperplasia: new trials by email Literature Review of Prostatic Hyperplasia trials Research Report on Prostatic Hyperplasia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of DKF-313 in Patients With Benign Prostatic Hyperplasia DKF-313, Dutasteride, Tadalafil - Benign Prostatic Hyperplasia | Phase 3 | Completed | Dongkook Pharmaceutical Co., Ltd. | 667 | 2021-07-27 | 2023-09-21 |
| The Effectiveness of Spermotrend Food Supplement in the Treatment of Male Infertility Spermotrend - Male Infertility, Benign Prostatic Hyperplasia | Phase 2 / Phase 3 | Completed | Catalysis SL | 150 | 2021-06-15 | 2023-03-28 |
| Efficacy and Safety of Tanzânia Association in the Treatment of Erectile Dysfunction Associated With Benign Prostatic Hyperplasia Tanzânia association, Omnic Ocas, Omnic Ocas placebo - Erectile Dysfunction, Benign Prostatic Hyperplasia | Phase 3 | Completed | EMS | 295 | 2021-03-14 | 2025-12-08 |
| Composite Steep-pulseTreatment Device Used in Patients With Benign Prostatic Hyperplasia Composite Steep-pulse Treatment Device, Tamsulosin Hydrochloride Capsules - Benign Prostatic Hyperplasia | Phase 2 / Phase 3 | Completed | REMD Medical Technology | 160 | 2020-08-20 | 2022-09-07 |
| A Comparison of Traditional and MOSES Laser Enucleation of the Prostate (MOLEP): A Prospective, Randomized, Double-blinded Control Trial A Comparison of Traditional and MOSES Laser Enucleation of the Prostate (MOLEP): A Prospective, Randomized, Double-blinded Control Trial Moses laser enucleation of prostate - Benign Prostatic Hyperplasia | Phase 3 | Completed | Vanderbilt University Medical Center | 60 | 2020-01-01 | 2022-03-31 |
| Evaluate the Efficacy and Safety of GV1001 in Patients With Benign Prostatic Hyperplasia (BPH) GV1001 placebo, Proscar placebo - Benign Prostatic Hyperplasia (BPH) | Phase 3 | Completed | GemVax & Kael | 423 | 2019-10-30 | 2022-08-25 |
| Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia Vibegron - Overactive Bladder | Phase 3 | Completed | Urovant Sciences GmbH | 276 | 2019-09-19 | 2024-08-21 |
| Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) Vibegron, Placebo - Overactive Bladder | Phase 3 | Completed | Urovant Sciences GmbH | 1105 | 2019-03-26 | 2024-08-07 |
| HoLEP Vs BPEP for Large Prostatic Adenoma Holmium laser enucleation of the prostate versus bipolar transurethral enucleation of the prostate in management of benign prostatic hyperplasia - Prostate Hyperplasia | Phase 3 | Completed | Ahmed Maher Gamil Ahmed Higazy | 100 | 2018-02-01 | 2020-06-16 |
| Prostatic Artery Embolization Versus Medical Treatment in Symptomatic Benign Prostatic Hyperplasia Embosphere® (Prostatic Arteries Embolization), Drug therapy - Benign Prostatic Hyperplasia | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 90 | 2016-08-01 | 2022-05-03 |
| Efficacy Study of Fedovapagon for Nocturia in Men With Benign Prostatic Hyperplasia (BPH) Fedovapagon 2 mg, Placebo - Nocturia | Phase 2 / Phase 3 | Completed | Vantia Ltd | 432 | 2016-03-01 | 2018-10-31 |
| Clinical Trial to Compare the Solifenacin/Tamsulosin Combination Therapy With Tamsulosin Monotherapy for LUTS Due to BPH Tamsulosin 0.2mg + Solifenacin 5mg, Tamsulosin 0.2mg + Placebo(Solifenacin) - Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia | Phase 3 | Completed | Jeil Pharmaceutical Co., Ltd. | 780 | 2016-02-01 | 2019-08-29 |
| Clinical Trial To Evaluate the Efficacy and Safety of CKD-397 in Benign Prostatic Hyperplasia Patients Tamsulosin 0.2mg, Tadalafil 5mg - Benign Prostatic Hyperplasia | Phase 3 | Completed | Chong Kun Dang Pharmaceutical | 455 | 2015-09-01 | 2017-08-11 |
| A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of HCP1303 Capsules HCP1303 capsule 5/0.2mg, HCP1303 capsule 5/0.4mg, HGP1201 - Benign Prostatic Hyperplasia | Phase 3 | Completed | Hanmi Pharmaceutical Company Limited | 510 | 2015-03-01 | 2016-10-13 |
| A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of HGP0412 and HIP1402 in Patients With BPH Placebo, HGP0412 capsule, HIP1402 capsule - Benign Prostate Hyperplasia | Phase 3 | Completed | Hanmi Pharmaceutical Company Limited | 494 | 2014-10-01 | 2016-10-13 |
| Study to Investigate the Efficacy and Safety of GL2702 GLARS-NF1tablet and Harnal-D - Tablet in BPH Patients With LUTS Tamsulosin HCL 0.4mg, Tamsulosin HCL 0.2mg - Benign Prostatic Hyperplasia | Phase 3 | Completed | GL Pharm Tech Corporation | 309 | 2014-03-01 | 2016-02-25 |
| Study to Compare the Efficacy and Safety of Combination Treatment With Dutasteride and Tamsulosin With Tamsulosin Monotherapy, in Men With Moderate to Severe Benign Prostatic Hyperplasia Dutasteride 0.5mg capsules, Dutasteride placebo capsules, Tamsulosin 0.2mg tablets - Prostatic Hyperplasia | Phase 3 | Completed | GlaxoSmithKline | 607 | 2014-02-10 | 2019-04-05 |
| Randomized, Double-Blind, Vehicle-Controlled, Multicenter Safety and Efficacy Study of Intraprostatic PRX302 for LUTS BPH PRX302, Placebo - Benign Prostatic Hyperplasia | Phase 3 | Completed | Sophiris Bio Corp | 479 | 2013-10-01 | 2017-04-27 |
| A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED) 5 mg Tadalafil, Placebo, 0.2 mg Tamsulosin - Benign Prostate Hyperplasia, Erectile Dysfunction | Phase 3 | Completed | Eli Lilly and Company | 909 | 2013-09-01 | 2017-06-20 |
| Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022) NX-1207 - Benign Prostatic Hyperplasia, BPH | Phase 3 | Completed | Nymox Corporation | 160 | 2013-04-01 | 2017-03-10 |
Showing 20 of 64. Sign in to see all of them.
Lower Urinary Tract Symptoms (10) · Erectile Dysfunction (3) · Prostatic Neoplasms (2) · Urinary Bladder Neck Obstruction (2) · Urinary Bladder, Overactive (2) · Genital Diseases, Male (1) · Hyperplasia (1) · Infertility, Male (1) · Metabolic Syndrome (1) · Neoplasms (1) · Nocturia (1) · Prostatic Diseases (1) · Prostatitis (1) · Sexual Dysfunction, Physiological (1)
Genital Diseases (64) · Male Urogenital Diseases (64) · Urogenital Diseases (64) · Genital Diseases, Male (63) · Prostatic Diseases (63) · Pathological Conditions, Signs and Symptoms (15) · Signs and Symptoms (14) · Urological Manifestations (14) · Female Urogenital Diseases (6) · Female Urogenital Diseases and Pregnancy Complications (6) · Urologic Diseases (6) · Lower Urinary Tract Symptoms (4) · Urinary Bladder Diseases (4) · Mental Disorders (3) · Sexual Dysfunction, Physiological (3)
Tamsulosin (13) · Tadalafil (12) · Dutasteride (5) · Finasteride (4) · alfuzosin (4) · fexapotide (4) · silodosin (4) · Solifenacin Succinate (3) · N-(4-((5-(hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)-4-oxo-4,6,7,8-tetrahydropyrrolo(1,2-a)pyrimidine-6-carboxamide (2) · Biofeedback, Psychology (1) · Botulinum Toxins, Type A (1) · Doxazosin (1) · Drug Therapy (1) · Duration of Therapy (1) · Levofloxacin (1)
Eli Lilly and Company (10) · GlaxoSmithKline (5) · Sanofi (5) · Health Ever Bio-Tech Co., Ltd. (4) · Nymox Corporation (4) · Watson Pharmaceuticals (3) · AEterna Zentaris (2) · Astellas Pharma Europe B.V. (2) · Hanmi Pharmaceutical Company Limited (2) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2) · Urovant Sciences GmbH (2) · Aberdeen Royal Infirmary (1) · Ahmed Maher Gamil Ahmed Higazy (1) · Assistance Publique - Hôpitaux de Paris (1) · CMX Research (1)
United States (26) · Italy (11) · Canada (9) · France (9) · South Korea (9) · Germany (8) · Poland (8) · Belgium (6) · Japan (6) · Mexico (6) · Netherlands (6) · Russia (6) · United Kingdom (6) · Greece (5) · Taiwan (5)
Allan J Pantuck, MD, MS, FACS (2) · Lawrence Hill, PharmD, RPh (2) · Andrew Avins, MD, MPH (1) · Cathryn Glazener, MD (1) · Choung-Soo Kim, M.D.,Ph.D (1) · Christopher Re Chapple, BSc MD (1) · Claus Roehrborn (1)
PMID 26299520, PMID 21135869, PMID 23234617, PMID 11796283, PMID 12689743, PMID 12893330, PMID 14681504, PMID 16467543, PMID 16536764, PMID 18355417, PMID 18722631, PMID 19371887, PMID 19409693, PMID 19815265, PMID 20163842, PMID 21109344, PMID 21871706, PMID 22017520, PMID 22297243, PMID 23346990, PMID 24119319, PMID 24571205, PMID 24938580, PMID 25353053, PMID 25712312, PMID 26945662, PMID 29383480, PMID 29490509, PMID 30680237, PMID 37070660, PMID 37415648, PMID 40683564, PMID 41363221
2008 (2), 2018 (2), R01DK056199 (1), U01DK046472 (1)